0000899243-21-003639.txt : 20210128
0000899243-21-003639.hdr.sgml : 20210128
20210128190037
ACCESSION NUMBER: 0000899243-21-003639
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210126
FILED AS OF DATE: 20210128
DATE AS OF CHANGE: 20210128
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sinha Uma
CENTRAL INDEX KEY: 0001742587
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38533
FILM NUMBER: 21567255
MAIL ADDRESS:
STREET 1: C/O EIDOS THERAPEUTICS, INC.
STREET 2: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Eidos Therapeutics, Inc.
CENTRAL INDEX KEY: 0001731831
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 463733671
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
BUSINESS PHONE: 650-391-9740
MAIL ADDRESS:
STREET 1: 101 MONTGOMERY STREET, SUITE 2550
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94104
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-01-26
1
0001731831
Eidos Therapeutics, Inc.
EIDX
0001742587
Sinha Uma
C/O EIDOS THERAPEUTICS, INC.
101 MONTGOMERY STREET, SUITE 2000
SAN FRANCISCO
CA
94104
0
1
0
0
Chief Scientific Officer
Common Stock
2020-10-27
4
G
0
3000
0.00
D
303525
D
Common Stock
2021-01-26
4
U
0
303525
D
0
D
Stock Option (Right to Buy)
13.20
2021-01-26
4
D
0
60000
D
2028-11-05
Common Stock
60000
0
D
Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). At the Effective Time, each shares of Issuer common stock that was outstanding and held by the Reporting Person immediately prior to the Effective Time was cancelled and automatically converted into 1.85 shares of Parent common stock.
The option vests over four years after November 5, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
/s/ Franco Valle, Attorney-in-Fact
2021-01-28